Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
129.16
-0.02 (-0.02%)
At close: Jun 5, 2026, 4:00 PM EDT
128.53
-0.63 (-0.49%)
After-hours: Jun 5, 2026, 7:56 PM EDT
Gilead Sciences Employees
Gilead Sciences had 17,000 employees as of December 31, 2025. The number of employees decreased by 600 or -3.41% compared to the previous year.
Employees
17,000
Change (1Y)
-600
Growth (1Y)
-3.41%
Revenue / Employee
$1,749,176
Profits / Employee
$542,118
Market Cap
160.36B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17,000 | -600 | -3.41% |
| Dec 31, 2024 | 17,600 | -400 | -2.22% |
| Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
| Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
| Dec 31, 2021 | 14,400 | 800 | 5.88% |
| Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
| Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
| Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
| Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
| Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
| Jan 31, 2015 | 7,000 | 900 | 14.75% |
| Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
| Jan 31, 2013 | 5,000 | 500 | 11.11% |
| Jan 31, 2012 | 4,500 | 500 | 12.50% |
| Jan 31, 2011 | 4,000 | 148 | 3.84% |
| Jan 31, 2010 | 3,852 | 411 | 11.94% |
| Jan 31, 2009 | 3,441 | 462 | 15.51% |
| Jan 31, 2008 | 2,979 | 464 | 18.45% |
| Jan 31, 2007 | 2,515 | 615 | 32.37% |
| Jan 31, 2006 | 1,900 | 246 | 14.87% |
| Feb 28, 2005 | 1,654 | 229 | 16.07% |
| Feb 27, 2004 | 1,425 | 175 | 14.00% |
| Feb 28, 2003 | 1,250 | 250 | 25.00% |
| Feb 28, 2002 | 1,000 | 150 | 17.65% |
| Feb 28, 2001 | 850 | 90 | 11.84% |
| Dec 31, 1999 | 760 | 467 | 159.39% |
| Dec 31, 1998 | 293 | 4 | 1.38% |
| Dec 31, 1997 | 289 | 41 | 16.53% |
| Dec 31, 1996 | 248 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
GILD News
- 2 days ago - Gilead announces launch of lenacapavir in South Africa - TheFly
- 2 days ago - Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa - Business Wire
- 3 days ago - GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE - GlobeNewsWire
- 3 days ago - Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline - Business Wire
- 5 days ago - Gilead announces results from Phase 3 study of Livdelzi - TheFly
- 5 days ago - Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) - Business Wire
- 10 days ago - Gilead Sciences Transcript: Bernstein 42nd Annual Strategic Decisions Conference - Transcripts
- 11 days ago - Gilead presents new Livdelzi data at EASL congress - TheFly